← Back to Clinical Trials
Recruiting NCT06135571

NCT06135571 Study on the No.253 Lymph Node Metastasis Patterns in Left-Sided Colon and Rectal Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06135571
Status Recruiting
Phase
Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Condition Colorectal Cancer
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2023-09-01
Primary Completion 2024-09-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 75 Years
Study Type OBSERVATIONAL
Interventions
Laparoscopic colorectal surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2023-09-01 with a primary completion date of 2024-09-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this observational study is to learn about the the pattern of metastasis of the No.253 lymph node in colorectal cancer. The main questions it aims to answer are: 1. What are the risk factors for metastasis to the No.253 lymph node? 2.What is the prognosis for patients with metastasis to the No.253 lymph node? Patients with descending colon cancer, sigmoid colon cancer, and rectal cancer who undergo curative surgery with dissection of the No.253 lymph node are included in this study

Eligibility Criteria

Inclusion Criteria: 1. Age: 18-75 years; 2. Underwent laparoscopic left hemicolectomy, sigmoid colectomy, or rectal cancer radical surgery. 3. Postoperative pathology confirmed as adenocarcinoma. 4. No evidence of distant metastasis. Exclusion Criteria: 1. Previous history of malignant colorectal tumors. 2. Patients who have undergone multiple abdominal-pelvic surgeries. 3. Patients undergoing emergency surgery due to complications such as intestinal obstruction, intestinal perforation, or intestinal bleeding. 4. Surgery did not achieve R0 resection. 5. Patients with concurrent other malignant tumors or multiple primary colorectal cancers. 6. Patients unwilling to sign an informed consent or follow the study protocol for follow-up.

Contact & Investigator

Central Contact

Qian Liu, Dr.

✉ fcwpumch@163.com

📞 13601008906

Frequently Asked Questions

Who can join the NCT06135571 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Colorectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06135571 currently recruiting?

Yes, NCT06135571 is actively recruiting participants. Contact the research team at fcwpumch@163.com for enrollment information.

Where is the NCT06135571 trial being conducted?

This trial is being conducted at Beijing, China, Beijing, China, Beijing, China, Beijing, China.

Who is sponsoring the NCT06135571 clinical trial?

NCT06135571 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. The trial plans to enroll 3,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology